Literature DB >> 8648693

Longitudinal studies of viral sequence, viral phenotype, and immunologic parameters of human immunodeficiency virus type 1 infection in perinatally infected twins with discordant disease courses.

C Hutto1, Y Zhou, J He, R Geffin, M Hill, W Scott, C Wood.   

Abstract

Perinatal human immunodeficiency virus type 1 (HIV-1) infections cause a broad spectrum of clinical disease and are variable in both the age of the patient at onset of serious disease and the progression of the clinical course. Heterozygotic perinatally infected twins with a marked difference in their clinical courses were monitored during the first 2 years of life. Twin B, the second-born twin, developed AIDS by 6 months of age and died at 22 months of age, while twin A remained minimally symptomatic through the first 2 years. Sequential blood specimens were obtained from the twins in order to characterize the immunologic properties of the children and the phenotypes and genotypes of the HIV-1 isolates at various times. Twin A developed neutralizing antibodies and a high-level antibody-mediated cellular cytotoxicity (ADCC) response, while twin B had no neutralizing antibody and a much lower ADCC response. The virus isolates obtained from the two children at various time points proliferated equally well in peripheral blood mononuclear cells, were nonsyncytium inducing, and could not infect established T-cell lines. They differed in their ability to infect primary macrophages. In parallel to the biological studies, the HIV-1 tat and part of the env gene sequences of the longitudinal isolates at four time points were determined. Sequences of virus from both twins at different time points were highly conserved; the viruses evolved at a similar rate until the last analyzed time point, at which there was a dramatic increase in sequence diversity for the sicker child, especially in the tat gene. Our results show that the viruses isolated at different times do not have significant changes in growth properties. The absence or low levels of neutralizing antibodies may correlate with disease progression in the twins.

Entities:  

Mesh:

Year:  1996        PMID: 8648693      PMCID: PMC190234     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus.

Authors:  C Cheng-Mayer; C Weiss; D Seto; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

2.  The viral envelope gene is involved in macrophage tropism of a human immunodeficiency virus type 1 strain isolated from brain tissue.

Authors:  Z Q Liu; C Wood; J A Levy; C Cheng-Mayer
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

3.  Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality.

Authors:  M Tersmette; J M Lange; R E de Goede; F de Wolf; J K Eeftink-Schattenkerk; P T Schellekens; R A Coutinho; J G Huisman; J Goudsmit; F Miedema
Journal:  Lancet       Date:  1989-05-06       Impact factor: 79.321

4.  Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization.

Authors:  R J Grimaila; B A Fuller; P D Rennert; M B Nelson; M L Hammarskjöld; B Potts; M Murray; S D Putney; G Gray
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

5.  Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants.

Authors:  S M Wolinsky; C M Wike; B T Korber; C Hutto; W P Parks; L L Rosenblum; K J Kunstman; M R Furtado; J L Muñoz
Journal:  Science       Date:  1992-02-28       Impact factor: 47.728

6.  Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120.

Authors:  C Cheng-Mayer; T Shioda; J A Levy
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

7.  Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle.

Authors:  J A Zack; A M Haislip; P Krogstad; I S Chen
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

8.  Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene.

Authors:  T Shioda; J A Levy; C Cheng-Mayer
Journal:  Nature       Date:  1991-01-10       Impact factor: 49.962

9.  Longitudinal study of 94 symptomatic infants with perinatally acquired human immunodeficiency virus infection. Evidence for a bimodal expression of clinical and biological symptoms.

Authors:  S Blanche; M Tardieu; A Duliege; C Rouzioux; F Le Deist; K Fukunaga; M Caniglia; C Jacomet; A Messiah; C Griscelli
Journal:  Am J Dis Child       Date:  1990-11

10.  Clinical significance of human immunodeficiency virus type 1 phenotypes in infected children.

Authors:  L T Spencer; M T Ogino; W M Dankner; S A Spector
Journal:  J Infect Dis       Date:  1994-03       Impact factor: 5.226

View more
  13 in total

1.  Genetic variation in a human immunodeficiency virus type 2 live-virus Macaca nemestrina vaccine model.

Authors:  A Radaelli; G Kraus; A Schmidt; P Badel; J McClure; S L Hu; W Morton; C De Giuli Morghen; F Wong-Staal; D Looney
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

2.  Evolution of human immunodeficiency virus type 1 in perinatally infected infants with rapid and slow progression to disease.

Authors:  F Salvatori; S Masiero; C Giaquinto; C M Wade; A J Brown; L Chieco-Bianchi; A De Rossi
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

3.  Intrapatient diversity and its correlation with viral setpoint in human immunodeficiency virus type 1 CRF02_A/G-IbNG infection.

Authors:  Indu Mani; Peter Gilbert; Jean-Louis Sankalé; Geoffrey Eisen; Souleymane Mboup; Phyllis J Kanki
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

4.  Viral diversity and diversification of major non-structural genes vif, vpr, vpu, tat exon 1 and rev exon 1 during primary HIV-1 subtype C infection.

Authors:  Raabya Rossenkhan; Vladimir Novitsky; Theresa K Sebunya; Rosemary Musonda; Berhanu A Gashe; M Essex
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

5.  Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.

Authors:  A Trkola; T Ketas; V N Kewalramani; F Endorf; J M Binley; H Katinger; J Robinson; D R Littman; J P Moore
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

Review 6.  HIV-1 co-receptor usage: influence on mother-to-child transmission and pediatric infection.

Authors:  Mariangela Cavarelli; Gabriella Scarlatti
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

7.  Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant.

Authors:  Hong Zhang; Federico Hoffmann; Jun He; Xiang He; Chipepo Kankasa; Ruth Ruprecht; John T West; Guillermo Orti; Charles Wood
Journal:  Retrovirology       Date:  2005-11-07       Impact factor: 4.602

8.  Amaranth oil application for coronary heart disease and hypertension.

Authors:  Danik M Martirosyan; Lidia A Miroshnichenko; Svetlana N Kulakova; Ala V Pogojeva; Vladimir I Zoloedov
Journal:  Lipids Health Dis       Date:  2007-01-05       Impact factor: 3.876

9.  Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease.

Authors:  Hong Zhang; Federico Hoffmann; Jun He; Xiang He; Chipepo Kankasa; John T West; Charles D Mitchell; Ruth M Ruprecht; Guillermo Orti; Charles Wood
Journal:  Retrovirology       Date:  2006-10-20       Impact factor: 4.602

10.  Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals.

Authors:  Jennifer L Greenier; Koen K A Van Rompay; David Montefiori; Patricia Earl; Bernard Moss; Marta L Marthas
Journal:  Virol J       Date:  2005-02-14       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.